April 4, 2017 / 5:40 AM / in 4 months

BRIEF-Galapagos announces three new phase 2 Proof-of-Concept studies with filgotinib

1 Min Read

April 4 (Reuters) - Galapagos NV:

* Galapagos announces three new phase 2 Proof-of-Concept studies with filgotinib

* Trials for filgotinib in Sjögren's syndrome, in ankylosing spondylitis (as), and in psoriatic arthritis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below